KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xenon Pharmaceuticals (XENE) Change in Cash: 2013-2025

Historic Change in Cash for Xenon Pharmaceuticals (XENE) over the last 11 years, with Sep 2025 value amounting to -$30.9 million.

  • Xenon Pharmaceuticals' Change in Cash rose 37.15% to -$30.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $16.9 million, marking a year-over-year increase of 241.33%. This contributed to the annual value of -$5.9 million for FY2024, which is 106.49% down from last year.
  • Latest data reveals that Xenon Pharmaceuticals reported Change in Cash of -$30.9 million as of Q3 2025, which was down 264.85% from $18.7 million recorded in Q2 2025.
  • Xenon Pharmaceuticals' 5-year Change in Cash high stood at $253.4 million for Q2 2022, and its period low was -$266.5 million during Q3 2022.
  • Its 3-year average for Change in Cash is $4.3 million, with a median of $12.3 million in 2023.
  • Data for Xenon Pharmaceuticals' Change in Cash shows a peak YoY increase of 5,113.77% (in 2022) and a maximum YoY decrease of 5,562.14% (in 2022) over the last 5 years.
  • Xenon Pharmaceuticals' Change in Cash (Quarterly) stood at $87.9 million in 2021, then crashed by 152.63% to -$46.2 million in 2022, then surged by 206.10% to $49.1 million in 2023, then climbed by 12.27% to $55.1 million in 2024, then skyrocketed by 37.15% to -$30.9 million in 2025.
  • Its Change in Cash stands at -$30.9 million for Q3 2025, versus $18.7 million for Q2 2025 and -$26.1 million for Q1 2025.